A speedy FDA of­fers light­ning re­view and quick OK for the lat­est PD-1 from Re­gen­eron and Sanofi

The FDA re­al­ly didn’t need un­til the end of Oc­to­ber to de­cide on whether it want­ed to ap­prove cemi­plimab, the world’s 6th PD-1/L1 from Sanofi and Re­gen­eron. Reg­u­la­tors flagged it through on Fri­day evening, hap­py to see the field crowd up as a top col­lab­o­ra­tion team cruised to a win ahead of a pri­or­i­ty re­view dead­line.

The drug will be sold as Lib­tayo for ad­vanced cu­ta­neous squa­mous cell car­ci­no­ma. In­ves­ti­ga­tors came up with a 46.3% ORR for ad­vanced CSCC in their key study and plan to sell the ther­a­py with a whole­sale ac­qui­si­tion cost of $9,100 per three-week treat­ment cy­cle. Pa­tients will be el­i­gi­ble for co­pay sup­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER